- Naranj Research Desk
- 🇸🇦 Saudi Stock Market
- 🇺🇸 USA Stock Market
5% – 6%
12 - 14 Days
5% – 6%
12 - 14 Days
| Metric | Q2 FY26 (Jul '26) | Q1 FY26 (Apr '26) | Q2 FY25 (Jul '25) | QoQ Change | YoY Change |
|---|---|---|---|---|---|
| Total Revenue (GAAP) | $729.7 M | $710.1 M | $720.3 M | ▲ 2.7% | ▲ 1.3% |
| Pro Forma Revenue (ex-China IDx) | $711.0 M | ~$690 M | ~$683 M | ▲ ~3.0% | ▲ ~4.1% |
| GAAP Gross Margin | 57.10% | ~54.5% | 54.50% | ▲ ~260 bps | ▲ 260 bps |
| Adj. Operating Income | $211.0 M | ~$185 M | $191.5 M | ▲ ~14.1% | ▲ 10.2% |
| Adj. Operating Margin | 29.30% | ~26.8% | 27.00% | ▲ ~250 bps | ▲ 230 bps |
| GAAP Net Income | $51.8 M | ~$75 M | $52.6 M | ▼ ~30.7% | ▼ 1.5% |
| GAAP Diluted EPS | $0.48 | ~$0.70 | $0.47 | ▼ ~31.4% | ▲ 2.1% |
| Adj. Diluted EPS | $1.41 | ~$1.27 | $1.18 | ▲ ~11.0% | ▲ 19.5% |
RVTY — NYSE —
| Indicator | Value | Zone |
|---|---|---|
| RSI-14 | 59.38 | Neutral |
| CCI-14 | 14.83 | Neutral |
| ROC | 4.54 | Positive |
| Stochastic RSI | 48.59 | Neutral |
| William %R | -36.51 | Neutral |
| EMA | Value | Stock Position |
|---|---|---|
| 5 EMA | 126.13 | Above |
| 10 EMA | 125.98 | Above |
| 20 EMA | 124.39 | Above |
| 50 EMA | 118.07 | Above |
| 100 EMA | 112.12 | Above |
| 200 EMA | 105.81 | Above |
Based on our daily trading calls in USA stocks, Revvity stock price target will be USD 134 - USD 136 in the next 12-14 trading sessions.
5% – 6%
12 - 14 Days
5% – 6%
12 - 14 Days
Revvity, Inc. is a US-based health sciences company that provides instruments, reagents, software, and testing solutions for diagnostics, genomics, drug discovery, and research. Its products are used by pharmaceutical companies, laboratories, hospitals, researchers, and government agencies. The company was founded in 1937 and was formerly known as PerkinElmer before changing its name to Revvity in 2023.
| Metric | Q2 FY26 (Jul '26) | Q1 FY26 (Apr '26) | Q2 FY25 (Jul '25) | QoQ Change | YoY Change |
|---|---|---|---|---|---|
| Total Revenue (GAAP) | $729.7 M | $710.1 M | $720.3 M | ▲ 2.7% | ▲ 1.3% |
| Pro Forma Revenue (ex-China IDx) | $711.0 M | ~$690 M | ~$683 M | ▲ ~3.0% | ▲ ~4.1% |
| GAAP Gross Margin | 57.10% | ~54.5% | 54.50% | ▲ ~260 bps | ▲ 260 bps |
| Adj. Operating Income | $211.0 M | ~$185 M | $191.5 M | ▲ ~14.1% | ▲ 10.2% |
| Adj. Operating Margin | 29.30% | ~26.8% | 27.00% | ▲ ~250 bps | ▲ 230 bps |
| GAAP Net Income | $51.8 M | ~$75 M | $52.6 M | ▼ ~30.7% | ▼ 1.5% |
| GAAP Diluted EPS | $0.48 | ~$0.70 | $0.47 | ▼ ~31.4% | ▲ 2.1% |
| Adj. Diluted EPS | $1.41 | ~$1.27 | $1.18 | ▲ ~11.0% | ▲ 19.5% |
RVTY — NYSE —
| Indicator | Value | Zone |
|---|---|---|
| RSI-14 | 59.38 | Neutral |
| CCI-14 | 14.83 | Neutral |
| ROC | 4.54 | Positive |
| Stochastic RSI | 48.59 | Neutral |
| William %R | -36.51 | Neutral |
| EMA | Value | Stock Position |
|---|---|---|
| 5 EMA | 126.13 | Above |
| 10 EMA | 125.98 | Above |
| 20 EMA | 124.39 | Above |
| 50 EMA | 118.07 | Above |
| 100 EMA | 112.12 | Above |
| 200 EMA | 105.81 | Above |
Based on our daily trading calls in USA stocks, Revvity stock price target will be USD 134 - USD 136 in the next 12-14 trading sessions.
